GlassScriptPhysician profile
Kenneth Albert Cearlock
NPI 1144214123
$5,458.79
in general payments reported to CMS, 2019-2025
31 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $60.94 · 2021: $539 · 2022: $1,131 · 2023: $1,266 · 2024: $1,093 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,312.34 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $962.76 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $502.88 | 2019-2025 | |
| Lilly USA, LLC | $501.53 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $436.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $203.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $175.36 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Biohaven Pharmaceutical Holding Company LTD. | $160.37 | 2022 | |
| Exact Sciences Corporation | $143.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $127.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.92 | 2019-2022 | |
| Mylan Specialty L.P. | $81.70 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $77.41 | 2019 | |
| Merck Sharp & Dohme LLC | $72.31 | 2022-2023 | Belsomra, Verquvo |
| Phathom Pharmaceuticals, INC. | $71.29 | 2024 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.44 | 2021-2024 | Tradjenta, Synjardy, Jardiance |
| Abbott Laboratories | $60.39 | 2024-2025 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $49.49 | 2024-2025 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $42.42 | 2023 | Quviviq |
| Allergan, INC. | $42.08 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.93 | 2022-2023 | |
| Genentech USA, INC. | $32.74 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $32.38 | 2021 | |
| Astellas Pharma US INC | $32.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.83 | 2021 | |
| Shire North American Group INC | $24.47 | 2019 | |
| Aimmune Therapeutics, INC. | $22.59 | 2024 | |
| Ironwood Pharmaceuticals, INC | $18.89 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.19 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.51 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Cearlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.